Cepheid, Others Look Beyond Respiratory Infections in the Molecular POC Diagnostics Market

Companies looking beyond the clinical lab in the molecular diagnostics market predominately target rapid test demand in primary care and critical care, chiefly respiratory infections. All CLIA waivers to date for molecular tests have been for respiratory infections (influenza, strep A, RSV), though equally ample and more promising markets for molecular point-of-care (POC) diagnostics market will be found in other areas - including women’s health/sexual health and high-burden diseases in the deve...


Infectious Disease Updates - Zika Virus, Lyme Disease and the U.S. Influenza Season

Infectious Disease Updates - Zika Virus, Lyme Disease and the U.S. Influenza Season

Kalorama Information offers complete analysis of the global infectious disease diagnostics market with its recent title The World Market for Infectious Disease Diagnostic Tests. Previous posts in this blog reviewed infectious disease test market segments for hospital-acquired infections (HAIs); antimicrobial resistance ; women’s health and sexually transmitted pathogens , hepatitis , HIV/AIDS , and respiratory tract infection tests.

Influenza in the United States

The United States is experie...


Top Infectious Diseases in the IVD Market - Respiratory Tract Infections

Top Infectious Diseases in the IVD Market - Respiratory Tract Infections

The following analysis is derived from Kalorama Information’s recently released global market research report: The Worldwide Market for Infectious Disease Diagnostic Tests.

This is the first in a series of five posts outlining the leading infectious diseases or disease groups in terms of IVD market sales - beginning with tests for respiratory tract infections.

At well over $1 billion in IVD market space, tests for respiratory tract infections are supported by all three of the major diagnosti...

  • by bcarlson@marketresearch.com
  • May 6 2014
  • vaccine
  • flu


Vaccine Revenues Near 24 Billion

Vaccine Revenues Near 24 Billion

In 2013, the world market for preventive vaccines totaled $23.9 billion, up from $22.8 billion in 2012 as sales in all segments expanded, according to our latest report. Among some the growth leaders was influenza vaccines, where greater awareness, new products and overstock recovery lead to 3.1 billion in revenues, up from 2.8 billion in 2012.

The influenza increase is significant according to Kalorama because there had been a large decrease in the influenza vaccine market in 2011. Vaccines s...